De Caterina R, Lip GYH (2017) The non-vitamin K antagonist oral anticoagulants (NOACs) and extremes of body weight-a systematic literature review. Clin Res Cardiol 106:565–572. https://doi.org/10.1007/s00392-017-1102-5

Article  CAS  PubMed  Google Scholar 

Giugliano RP, Ruff CT, Eugene B et al (2013) Edoxaban versus Warfarin in patients with Atrial Fibrillation. N Engl J Med 369:2093–2104. https://doi.org/10.1056/NEJMoa1310907

Article  CAS  PubMed  Google Scholar 

The Hokusai-VTE Investigators (2013) Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism. N Engl J Med 369:1406–1415. https://doi.org/10.1056/NEJMoa1306638

Article  CAS  Google Scholar 

Frisullo G, Profice P, Brunetti V et al (2020) Prospective Observational Study of Safety of Early Treatment with Edoxaban in Patients with Ischemic Stroke and Atrial Fibrillation (SATES Study). Brain Sci 11:30. https://doi.org/10.3390/brainsci11010030

Article  CAS  PubMed  PubMed Central  Google Scholar 

China Medical Education Association (2023) Specification for risk management of high alert medications in medical institutions

Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356:1255–1259. https://doi.org/10.1016/S0140-6736(00)02799-9

Article  CAS  PubMed  Google Scholar 

International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) (2016) ICH harmonised guideline: Integrated addendum to ICH E6(R1): Guideline for good clinical practice E6(R2).

U.S. Food and Drug Administration website (2021) GENENTECH Company. RITUXAN (Rituximab). [package insert]

Lixiana 15mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (emc). https://www.medicines.org.uk/emc/product/6907/smpc. Accessed 11 Jan 2025

Steffel J, Collins R, Antz M et al (2021) 2021 European heart rhythm association practicalguide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 23:1612–1676. https://doi.org/10.1093/europace/euab065

Article  PubMed  PubMed Central  Google Scholar 

Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials. Circulation 123:2736–2747. https://doi.org/10.1161/CIRCULATIONAHA.110.009449

Article  PubMed  Google Scholar 

Yong CM, Tremmel JA, Lansberg MG et al (2020) Sex differences in oral anticoagulation and outcomes of stroke and intracranial bleeding in newly diagnosed atrial fibrillation. J Am Heart Assoc 9:e015689. https://doi.org/10.1161/JAHA.120.015689

Article  PubMed  PubMed Central  Google Scholar 

Proietti M, Cheli P, Basili S, Mazurek M and Lip GY (2017) Balancing thromboembolic and bleeding risk with non-vitamin K antagonist oral anticoagulants (NOACs): a systematic review and meta-analysis on gender differences. Pharmacol Res 117:274–282. https://doi.org/10.1016/j.phrs.2017.01.004

Zelniker TA, Ardissino M, Andreotti F et al (2021) Comparison of the efficacy and safety outcomes of Edoxaban in 8040 women versus 13 065 men with atrial fibrillation in the ENGAGE AF-TIMI 48 Trial. Circulation 143:673–684. https://doi.org/10.1161/CIRCULATIONAHA.120.052216

Article  CAS  PubMed  PubMed Central  Google Scholar 

Giner-Soriano M, Prat-Vallverdú O, Ouchi D et al (2023) Sex and gender differences in the use of oral anticoagulants for non-valvular atrial fibrillation: a population-based cohort study in primary health care in catalonia. Front Pharmacol 14:1110036. https://doi.org/10.3389/fphar.2023.1110036

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chao T-F, Chen S-A, Ruff CT et al (2019) Clinical outcomes, edoxaban concentration, and anti-factor Xa activity of Asian patients with atrial fibrillation compared with non-Asians in the ENGAGE AF-TIMI 48 trial. Eur Heart J 40:1518–1527. https://doi.org/10.1093/eurheartj/ehy807

Article  CAS  PubMed  Google Scholar 

Okumura K, Akao M, Yoshida T et al (2020) Low-dose Edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 383:1735–1745. https://doi.org/10.1056/NEJMoa2012883

Article  CAS  PubMed  Google Scholar 

Kato ET, Giugliano RP, Ruff CT et al (2016) Efficacy and safety of Edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 Trial. J Am Heart Assoc 5:e003432. https://doi.org/10.1161/JAHA.116.003432

Article  PubMed  PubMed Central  Google Scholar 

Ruff CT, Giugliano RP, Braunwald E et al (2015) Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 385:2288–2295. https://doi.org/10.1016/S0140-6736(14)61943-7

Article  CAS  PubMed  Google Scholar 

Lee OS, Kim W, Jang BM et al (2021) Association of risk factors and bleeding complications in Asian patients taking edoxaban. Br J Clin Pharmacol 87:2121–2127. https://doi.org/10.1111/bcp.14623

Article  CAS  PubMed  Google Scholar 

Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41. https://doi.org/10.1159/000180580

Article  CAS  PubMed  Google Scholar 

Ogata K, Mendell-Harary J, Tachibana M et al (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50:743–753. https://doi.org/10.1177/0091270009351883

Article  CAS  PubMed  Google Scholar 

Bohula EA, Giugliano RP, Ruff CT et al (2016) Impact of renal function on outcomes with Edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation 134:24–36. https://doi.org/10.1161/CIRCULATIONAHA.116.022361

Article  CAS  PubMed  Google Scholar 

Corsini A, Ferri N, Proietti M, Boriani G (2020) Edoxaban and the issue of drug-drug interactions: from pharmacology to clinical practice. Drugs 80:1065–1083. https://doi.org/10.1007/s40265-020-01328-6

Article  CAS  PubMed  Google Scholar 

Aller SG, Yu J, Ward A et al (2009) Structure of P-glycoprotein reveals a molecular basis for poly-specific drug binding. Science 323:1718–1722. https://doi.org/10.1126/science.1168750

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mo Y, Karakas-Torgut A, Pham AQ (2020) Evaluation of potential drug-drug interactions with direct oral anticoagulants in a large urban hospital. J Pharm Pract 33:136–141. https://doi.org/10.1177/0897190018788264

Article  PubMed  Google Scholar 

Nieuwlaat R, Prins MH, Le Heuzey J-Y et al (2008) Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the euro heart survey on atrial fibrillation. Eur Heart J 29:1181–1189. https://doi.org/10.1093/eurheartj/ehn139

Article  PubMed  Google Scholar 

Mendell J, Zahir H, Matsushima N et al (2013) Drug-drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs 13:331–342. https://doi.org/10.1007/s40256-013-0029-0

Article  CAS  PubMed  PubMed Central  Google Scholar 

Salazar DE, Mendell J, Kastrissios H et al (2012) Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation. Thromb Haemost 107:925–936. https://doi.org/10.1160/TH11-08-0566

Article  CAS  PubMed  Google Scholar 

Steffel J, Giugliano RP, Braunwald E et al (2015) Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial. Eur Heart J 36:2239–2245. https://doi.org/10.1093/eurheartj/ehv201

Article  CAS  PubMed  Google Scholar 

Boriani G, Blomström-Lundqvist C, Hohnloser SH et al (2019) Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation. Europace 21:1764–1775. https://doi.org/10.1093/europace/euz193

Article  PubMed  Google Scholar 

January CT, Wann LS, Calkins H, et al (2019) 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart rhythm society in collaboration with the society of thoracic surgeons. circulation 140:. https://doi.org/10.1161/CIR.0000000000000665

Wen H-N, He Q-F, Xiang X-Q et al (2022) Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration. Thromb Res 218:24–34.